Author: Leepan, Edward
Similar Items: An audit of the epidemiological, clinical features and outcomes of patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) attending a South African Tertiary referral Hospital
- Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder
- Neuromyelitis optica spectrum disorders with aquaporin-4 antibodies in patients with systemic rheumatic diseases
- AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab
- Integrated Blood Inflammatory Ratios and Cerebrospinal Fluid Blood‒Brain Barrier Dysfunction Predict Relapse Risk in Neuromyelitis Optica Spectrum Disorder
- Retrograde Maculopathy or Microcystic Macular Degeneration in Patients With Optic Neuritis due to Neuromyelitis Optica
- Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial